NCT01157793View on ClinicalTrials.gov

A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions
DwarfismGrowth Hormone Deficiency
Interventions
DRUG

r-hGH

r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route

DRUG

r-hGH

Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01157793 - A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood | Biotech Hunter | Biotech Hunter